甲状腺全切除术后放射性碘消融决策的差异调查
该研究分析瑞士所有提供放射性碘治疗的医院在分化型甲状腺癌全切除术后决策的差异。结果显示低危患者中部分机构仅随访、部分推荐显著活度放射性碘治疗,中高危患者普遍推荐放射性碘治疗,但剂量与准备方式(rhTSH vs 甲状腺激素撤停)在各中心间差异显著。
要点
- 低危分化型甲状腺癌全切除术后,各机构对是否行放射性碘治疗决策不一。
- 中高危患者普遍推荐放射性碘治疗。
- 各中心在放射性碘剂量及rhTSH与甲状腺激素撤停准备方式上差异显著。
核心结论
- 瑞士各医院在甲状腺全切除术后放射性碘治疗决策上存在显著差异,低危患者尤为明显。
研究设计与样本
- 分析瑞士所有提供放射性碘治疗的医院的决策制定,以描绘当前实践并识别共识与差异。
主要发现
- 低危分化型甲状腺癌全切除术后,部分机构仅提供随访,而其他机构推荐显著活度的放射性碘治疗。
- 中高危患者普遍推荐放射性碘治疗。
- 各中心在剂量及治疗准备方式(rhTSH vs 甲状腺激素撤停)上差异显著。
临床怎么用
- 核医学科医生应认识到低危分化型甲状腺癌术后放射性碘治疗决策存在机构间差异,需结合指南与患者情况个体化选择。
- 中高危患者普遍推荐放射性碘治疗,但剂量与准备方式需根据本中心方案及患者特点确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today. METHODS: We analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND CONCLUSION: We demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.
引用
- Maas O, Forrer F, Maas M, et al. Variations in radioiodine ablation: decision-making after total thyroidectomy. Eur J Nucl Med Mol Imaging. 2019. PMID: 31707428. doi:10.1007/s00259-019-04557-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。